25 September 2024
25 September 2024
Coverage for its long-acting insulin, Levamir, dropped from 90% to about 35% when the company dropped its list price by 65%.
Telix has paid an upfront cost of $230m to acquire 31 licensed radiopharmacies from RLS across the US.
Iterum Therapeutics faces a mixed reception for its therapy for uncomplicated urinary tract infections (UTIs) as experts raise concerns about antibiotic resistance.
The vaccine bulk manufacturing is scheduled for 2025 with the delivery of the freeze-dried doses set for 2026.
Generate could receive more than $1bn in performance-based milestone payments, in addition to royalty payments.
The latest approval of FRUZAQLA is based on the outcomes of the international Phase III FRESCO-2 trial.
The approval is based on the double-blind, placebo-controlled Phase III TRAILBLAZER-ALZ 2 clinical study.
AI-enabled dynamic modular content can predict individual medication behaviours to tailor content for patients.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
